Loperamide Hydrochloride
Phase 3Small molecule
Johnson & JohnsonLoperamide Hydrochloride is one of 48 small molecule programs targeting Acute Diarrhea. It is currently in Phase 3.
2
Indications
4
Total Trials
2
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Loperamide Hydrochloride
Johnson & JohnsonPhase 3
Eylea
RegeneronPreclinical
PORTRAZZA
Eli LillyPreclinical
Emend IV
Merck & Co.Preclinical
Ketalar
AAultman Health Foundation
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Andriol
AAuxilium
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Gas-X
PPortuguese Oncology Institute, Coimbra
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Loperamide Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company